Main outcome measure Recurrent symptomatic VTE (independently and blindly adjudicated) over one year of follow-up.
Results Of 1213 women, 631 (51.3%) were classified as low risk and 591 discontinued oral anticoagulant treatment.
The illustration validates an XML document that the user chooses, either or catelog1against the XML Schema document
You need one schema and two XML files to validate against the schema.
Validate(Document Validation Handler); I use your code and this for validate XML. Create(reader, settings); I use your code and this for validate XML.
Process Schema Location; Xml Reader XMLvalidator = Xml Reader.
If you choose to participate, the online survey will be presented to you when you leave the Msdn Web site.
Visual Studio, when I open the file, validates it against the schema and lists errors perfectly. I expect to fail validation against DCL.xsd, but the validation is OK, not fail. I expect to fail validation against DCL.xsd, but the validation is OK, not fail.
Create and set the properties of an Xml Reader Settings object.Some patient subgroups with major provoking factors (eg, post-surgical VTE) have a low risk of recurrent VTE (1% at one year)1 and anticoagulants can be safely discontinued after short term treatment.2 However, more than 50% of patients with VTE do not have a major provoking factor.3 In these patients with unprovoked VTE, the risk of recurrent VTE is substantially higher; up to 10% in the first year after stopping short term treatment, 5% in the subsequent year,4 and 30% at eight years.5 Recurrent VTE is fatal in 3.6% of cases.6Oral anticoagulant treatment is effective at reducing the risk of recurrent VTE during treatment; oral anticoagulant treatment reduces the risk of recurrent VTE by 80-90%.7 Longer term oral anticoagulant treatment likely only delays recurrent VTE compared with short term treatment.8910 The highest bleeding risks are observed during initial oral treatment.Patients who do not bleed during this time, termed “anticoagulant experienced” patients, are at lower risk of major bleeding with ongoing treatment (1.3% per year).7 Major bleeding is fatal in 11.3% of affected patients.6Guidelines recommend long term anticoagulant treatment in patients with unprovoked VTE with non-high bleeding risks, but this is based on weak evidence (grade 2B)11 owing to closely balanced competing risks and burdens of recurrent VTE and major bleeding.Somehow, though, I can't seem to validate it automatically in C# without specifying the schema to validate against like so: Xml Document asset = new Xml Document(); Xml Text Reader schema Reader = new Xml Text Reader("relative Schema Path"); Xml Schema schema = Xml Schema. I try using 7 several methods for validate XML using XSD, but all fails for me. I try using 7 several methods for validate XML using XSD, but all fails for me.Read(schema Reader, Schema Validation Handler); asset. Files (1 xsd, 2 xml) and full C# code here: gist.github.com/kiquenet/86090779650975b7426a7f798174eef6Xml Reader Settings settings = new Xml Reader Settings(); settings.
Conclusions Women with a first unprovoked VTE event and none or one of the HERDOO2 criteria have a low risk of recurrent VTE and can safely discontinue anticoagulants after completing short term treatment. Venous thromboembolism (VTE), comprising deep vein thrombosis and pulmonary embolism, is a common, potentially fatal yet treatable condition.